| Identification | Back Directory | [Name]
CL264 | [CAS]
1510712-69-2 | [Synonyms]
CL264
CL264,CL-264
(4-((6-amino-2-(butylamino)-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)benzoyl)glycine
Glycine, N-[4-[[6-amino-2-(butylamino)-7,8-dihydro-8-oxo-9H-purin-9-yl]methyl]benzoyl]- | [Molecular Formula]
C19H23N7O4 | [MOL File]
1510712-69-2.mol | [Molecular Weight]
413.43 |
| Chemical Properties | Back Directory | [density ]
1.427±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [pka]
3.65±0.10(Predicted) | [color ]
Brown to gray |
| Hazard Information | Back Directory | [Uses]
CL264 is a TLR7-specific agonist for innate immune signals research[1]. | [IC 50]
TLR7 | [References]
[1] Butterfield JSS, et al. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer. Hum Gene Ther Methods. 2019 Jun;30(3):81-92. DOI:10.1089/hgtb.2019.013 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|